Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Identifying prognostic structural features in tissue sections of colon cancer patients using point pattern analysis.

Jones-Todd CM, Caie P, Illian JB, Stevenson BC, Savage A, Harrison DJ, Bown JL.

Stat Med. 2019 Apr 15;38(8):1421-1441. doi: 10.1002/sim.8046. Epub 2018 Nov 28.

PMID:
30488481
2.

NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.

Kankia IH, Khalil HS, Langdon SP, Moult PR, Bown JL, Deeni YY.

Oxid Med Cell Longev. 2017;2017:1864578. doi: 10.1155/2017/1864578. Epub 2017 Dec 19.

3.

Kinetic modelling of in vitro data of PI3K, mTOR1, PTEN enzymes and on-target inhibitors Rapamycin, BEZ235, and LY294002.

Goltsov A, Tashkandi G, Langdon SP, Harrison DJ, Bown JL.

Eur J Pharm Sci. 2017 Jan 15;97:170-181. doi: 10.1016/j.ejps.2016.11.008. Epub 2016 Nov 8.

4.

A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells.

Khalil HS, Langdon SP, Goltsov A, Soininen T, Harrison DJ, Bown J, Deeni YY.

Oncotarget. 2016 Nov 15;7(46):75874-75901. doi: 10.18632/oncotarget.12425.

5.

A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT.

Bown JL, Shovman M, Robertson P, Boiko A, Goltsov A, Mullen P, Harrison DJ.

Oncotarget. 2017 May 2;8(18):29657-29667. doi: 10.18632/oncotarget.8747.

6.

NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.

Khalil HS, Langdon SP, Kankia IH, Bown J, Deeni YY.

Oxid Med Cell Longev. 2016;2016:4148791. doi: 10.1155/2016/4148791. Epub 2015 Dec 7.

7.

Quantitative analysis of NRF2 pathway reveals key elements of the regulatory circuits underlying antioxidant response and proliferation of ovarian cancer cells.

Khalil HS, Goltsov A, Langdon SP, Harrison DJ, Bown J, Deeni Y.

J Biotechnol. 2015 May 20;202:12-30. doi: 10.1016/j.jbiotec.2014.09.027. Epub 2014 Nov 5.

PMID:
25449014
8.

Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy.

Goltsov A, Deeni Y, Khalil HS, Soininen T, Kyriakidis S, Hu H, Langdon SP, Harrison DJ, Bown J.

Cells. 2014 Jun 10;3(2):563-91. doi: 10.3390/cells3020563.

9.

Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations.

Goltsov A, Langdon SP, Goltsov G, Harrison DJ, Bown J.

Front Oncol. 2014 Feb 5;4:13. doi: 10.3389/fonc.2014.00013. eCollection 2014.

10.

Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer.

Hu H, Goltsov A, Bown JL, Sims AH, Langdon SP, Harrison DJ, Faratian D.

Cell Signal. 2013 Jan;25(1):26-32. doi: 10.1016/j.cellsig.2012.09.014. Epub 2012 Sep 18.

PMID:
23000339
11.

Engineering simulations for cancer systems biology.

Bown J, Andrews PS, Deeni Y, Goltsov A, Idowu M, Polack FA, Sampson AT, Shovman M, Stepney S.

Curr Drug Targets. 2012 Nov;13(12):1560-74. Review.

PMID:
22974398
12.

Characterising the tumour morphological response to therapeutic intervention: an ex vivo model.

Savage A, Katz E, Eberst A, Falconer RE, Houston A, Harrison DJ, Bown J.

Dis Model Mech. 2013 Jan;6(1):252-60. doi: 10.1242/dmm.009886. Epub 2012 Aug 10.

13.

Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.

Goltsov A, Faratian D, Langdon SP, Mullen P, Harrison DJ, Bown J.

Cell Signal. 2012 Feb;24(2):493-504. doi: 10.1016/j.cellsig.2011.09.030. Epub 2011 Oct 4.

PMID:
21996585
14.

Modelling fungal colonies and communities: challenges and opportunities.

Falconer RE, Bown JL, McAdam E, Perez-Reche P, Sampson AT, van den Bulcke J, White NA.

IMA Fungus. 2010 Dec;1(2):155-9. Epub 2010 Nov 18.

15.

Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition.

Goltsov A, Faratian D, Langdon SP, Bown J, Goryanin I, Harrison DJ.

Cell Signal. 2011 Feb;23(2):407-16. doi: 10.1016/j.cellsig.2010.10.011. Epub 2010 Oct 14.

PMID:
20951800
16.

Cancer systems biology.

Faratian D, Bown JL, Smith VA, Langdon SP, Harrison DJ.

Methods Mol Biol. 2010;662:245-63. doi: 10.1007/978-1-60761-800-3_12. Review.

PMID:
20824475
17.

A novel ataxia-telangiectasia mutated autoregulatory feedback mechanism in murine embryonic stem cells.

Clyde RG, Craig AL, de Breed L, Bown JL, Forrester L, Vojtesek B, Smith G, Hupp T, Crawford J.

J R Soc Interface. 2009 Dec 6;6(41):1167-77. doi: 10.1098/rsif.2008.0538. Epub 2009 Mar 4.

18.

Modelling interactions in fungi.

Falconer RE, Bown JL, White NA, Crawford JW.

J R Soc Interface. 2008 Jun 6;5(23):603-15.

19.

The role of modelling in identifying drug targets for diseases of the cell cycle.

Clyde RG, Bown JL, Hupp TR, Zhelev N, Crawford JW.

J R Soc Interface. 2006 Oct 22;3(10):617-27. Review.

20.

Biomass recycling and the origin of phenotype in fungal mycelia.

Falconer RE, Bown JL, White NA, Crawford JW.

Proc Biol Sci. 2005 Aug 22;272(1573):1727-34.

Supplemental Content

Loading ...
Support Center